Optimistic Investors Push Japan Tissue Engineering Co., Ltd. (TSE:7774) Shares Up 27% But Growth Is Lacking
Dec 30
Have your own idea? Try our Stock Screener
Japanese (NIKKEI) Biotech Industry Analysis
UpdatedJan 04, 2026
DataAggregated Company Financials
Companies34
- 7D1.5%
- 3M-16.0%
- 1Y-12.7%
- YTDn/a
Over the last 7 days, the Biotech industry has risen 1.5%, driven by gains from Oncolys BioPharma of 26%. In the past year, the industry is down 13%. Looking forward, earnings are forecast to grow by 38% annually.
Industry Valuation and Performance
Has the Japanese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 05 Jan 2026 | JP¥998.4b | JP¥198.7b | -JP¥70,727,387,000.00 | 52.7x | -14.1x | 5x |
| Wed, 03 Dec 2025 | JP¥1.0t | JP¥196.3b | -JP¥69,433,658,500.00 | 50.2x | -14.6x | 5.2x |
| Fri, 31 Oct 2025 | JP¥1.1t | JP¥197.7b | -JP¥65,502,224,000.00 | 62.8x | -16.7x | 5.5x |
| Sun, 28 Sep 2025 | JP¥1.2t | JP¥197.7b | -JP¥65,794,561,000.00 | 66.7x | -17.6x | 5.9x |
| Tue, 26 Aug 2025 | JP¥1.2t | JP¥193.5b | -JP¥68,135,862,000.00 | 127.1x | -17.1x | 6x |
| Thu, 24 Jul 2025 | JP¥1.1t | JP¥218.2b | -JP¥43,758,567,000.00 | 104.3x | -26x | 5.2x |
| Sat, 21 Jun 2025 | JP¥1.2t | JP¥218.2b | -JP¥43,673,263,000.00 | 101.6x | -26.8x | 5.4x |
| Mon, 19 May 2025 | JP¥1.1t | JP¥214.5b | -JP¥40,387,244,000.00 | 14x | -26.5x | 5x |
| Wed, 16 Apr 2025 | JP¥994.3b | JP¥207.7b | -JP¥38,921,205,000.00 | 14.3x | -25.5x | 4.8x |
| Fri, 14 Mar 2025 | JP¥1.0t | JP¥207.1b | -JP¥39,288,682,000.00 | 15.9x | -25.9x | 4.9x |
| Sun, 09 Feb 2025 | JP¥1.0t | JP¥207.5b | -JP¥13,534,922,000.00 | 20.8x | -74x | 4.8x |
| Tue, 07 Jan 2025 | JP¥1.0t | JP¥207.3b | -JP¥13,531,081,000.00 | 21.6x | -77.5x | 5.1x |
| Thu, 05 Dec 2024 | JP¥1.1t | JP¥207.2b | -JP¥12,080,899,000.00 | 23x | -91.2x | 5.3x |
| Sat, 02 Nov 2024 | JP¥1.1t | JP¥214.3b | -JP¥3,941,502,000.00 | 22.4x | -272.4x | 5x |
| Mon, 30 Sep 2024 | JP¥1.1t | JP¥214.3b | -JP¥2,078,229,000.00 | 22x | -552.8x | 5.4x |
| Wed, 28 Aug 2024 | JP¥1.1t | JP¥210.1b | -JP¥580,439,000.00 | 18.1x | -1924.6x | 5.3x |
| Fri, 26 Jul 2024 | JP¥1.0t | JP¥187.7b | -JP¥15,871,901,000.00 | 92.7x | -65.2x | 5.5x |
| Sun, 23 Jun 2024 | JP¥897.9b | JP¥187.7b | -JP¥15,773,284,000.00 | 84.8x | -56.9x | 4.8x |
| Tue, 21 May 2024 | JP¥793.5b | JP¥195.9b | -JP¥13,410,545,000.00 | 94.9x | -59.2x | 4.1x |
| Thu, 18 Apr 2024 | JP¥732.7b | JP¥194.2b | -JP¥15,746,877,000.00 | 63.7x | -46.5x | 3.8x |
| Sat, 16 Mar 2024 | JP¥754.4b | JP¥194.2b | -JP¥18,497,301,000.00 | 57.9x | -40.8x | 3.9x |
| Mon, 12 Feb 2024 | JP¥747.3b | JP¥222.8b | -JP¥10,392,827,000.00 | 16.7x | -71.9x | 3.4x |
| Wed, 10 Jan 2024 | JP¥818.8b | JP¥222.3b | -JP¥12,668,455,000.00 | 17.6x | -64.6x | 3.7x |
| Fri, 08 Dec 2023 | JP¥765.6b | JP¥221.9b | -JP¥12,426,487,000.00 | 16.3x | -61.6x | 3.4x |
| Sun, 05 Nov 2023 | JP¥746.6b | JP¥223.0b | -JP¥14,350,085,000.00 | 19.3x | -52x | 3.3x |
| Tue, 03 Oct 2023 | JP¥823.8b | JP¥223.0b | -JP¥14,518,735,000.00 | 24.9x | -56.7x | 3.7x |
| Thu, 31 Aug 2023 | JP¥925.5b | JP¥225.1b | -JP¥19,814,131,000.00 | 49.8x | -46.7x | 4.1x |
| Sat, 29 Jul 2023 | JP¥902.0b | JP¥223.7b | -JP¥20,836,669,000.00 | 49.1x | -43.3x | 4x |
| Mon, 26 Jun 2023 | JP¥973.0b | JP¥223.2b | -JP¥20,139,670,000.00 | 64.6x | -48.3x | 4.4x |
| Wed, 24 May 2023 | JP¥930.9b | JP¥218.4b | -JP¥25,404,669,000.00 | 32.6x | -36.6x | 4.3x |
| Fri, 21 Apr 2023 | JP¥938.3b | JP¥218.1b | -JP¥20,115,522,000.00 | 21.4x | -46.6x | 4.3x |
| Sun, 19 Mar 2023 | JP¥935.3b | JP¥218.3b | -JP¥21,582,580,000.00 | 20.9x | -43.3x | 4.3x |
| Tue, 14 Feb 2023 | JP¥961.8b | JP¥200.4b | -JP¥25,348,917,000.00 | 38x | -37.9x | 4.8x |
| Thu, 12 Jan 2023 | JP¥918.5b | JP¥186.8b | -JP¥24,722,604,000.00 | 40.7x | -37.2x | 4.9x |
Price to Earnings Ratio
-37.2x
Current Industry PE
- Investors are relatively neutral on the Japanese Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 4.7x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 2.1% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Japanese Healthcare industry?
| JP Market | -0.44% | |
| Healthcare | -1.11% | |
| Biotech | 1.49% | |
| Biotech | 1.49% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 4588 Oncolys BioPharma | JP¥1.38k | 25.7% +JP¥8.1b | 167.2% | PS1386.8x | |
| 4592 SanBio | JP¥1.69k | 4.7% +JP¥5.5b | 125.0% | PB247.3x | |
| 7774 Japan Tissue Engineering | JP¥622.00 | 25.7% +JP¥5.2b | 34.3% | PS11x | |
| 4563 AnGes | JP¥61.00 | 3.4% +JP¥775.1m | 15.1% | PS28.9x | |
| 7776 CellSeed | JP¥259.00 | 7.9% +JP¥658.7m | -35.1% | n/a |
